Press Releases BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
1.26 ^USD	-2.33%		-7.35%	-27.58%

May. 15	BioRestorative Announces Signing a Five-Year Exclusive Supply Agreement with Cartessa Aesthetics, LLC	CI
May. 08	BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioRestorative Therapies Provides First Quarter 2024 Business Update	May. 14	AQ
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity	May. 08	AQ
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	Apr. 30	AQ
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology	Apr. 30	AQ
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	Apr. 16	AQ
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	Apr. 08	AQ
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants	Apr. 03	AQ
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K	Apr. 01	AQ
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference	Mar. 11	AQ
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market	Feb. 06	AQ
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	Feb. 05	AQ
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting	Feb. 01	AQ
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program	Dec. 12	AQ
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City	23-10-09	AQ
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics	23-09-12	AQ
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease	23-09-11	AQ
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease	23-09-08	AQ
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering	23-07-11	AQ
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes	23-06-27	AQ
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET	23-06-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Press Releases

Filters